Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits
of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

Abstract Context The European Association of Urology (EAU) has released an updated
version of the guidelines on non–muscle-invasive bladder cancer (NMIBC). Objective To …

Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …

Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

Bladder cancer, the sixth most common cancer in the United States, is most commonly of the
urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided …

Purpose: The purpose of this American Urological Association (AUA)/Society of Urologic
Oncology (SUO) guideline amendment is to provide a useful reference on the effective …

Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer without invasion into
the detrusor muscle layer. Transurethral resection of bladder tumour (TURBT) is a diagnostic …